Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer

Phase 3

Conditions: Colorectal Cancer

Interventions: Drug: Huaier Granule
Drug: Oxaliplatin
Drug: Calcium folinate
Drug: 5-fluorouracil

First Posted Date: 2016-05-27

Last Posted Date: 2016-06-08

Lead Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Target Recruit Count: 230

Registration Number: NCT02785146

Locations: 🇨🇳
Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

Completed

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: carboplatin
Drug: cisplatin
Drug: 5-FU

First Posted Date: 2016-05-19

Last Posted Date: 2024-05-06

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 413

Registration Number: NCT02778191

Locations: 🇳🇱
VUmc, Amsterdam, Netherlands
🇳🇱
University Medical Center Groningen, Groningen, Netherlands

The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery

Phase 3

Completed

Conditions: Glaucoma

Interventions: Drug: 5-fluorouracil
Drug: bevacizumab
Drug: Dexamethasone

First Posted Date: 2016-05-10

Last Posted Date: 2021-08-17

Lead Sponsor: Moorfields Eye Hospital NHS Foundation Trust

Target Recruit Count: 6

Registration Number: NCT02767219

Locations: 🇬🇧
Moorfields Eye Hospital, Clinical Research Facility, London, United Kingdom

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Napabucasin
Drug: Fluorouracil
Drug: Leucovorin
Drug: Irinotecan
Drug: Bevacizumab

First Posted Date: 2016-04-27

Last Posted Date: 2023-11-15

Lead Sponsor: Sumitomo Pharma America, Inc.

Target Recruit Count: 1253

Registration Number: NCT02753127

Locations: 🇺🇸
Illinois Cancer Specialists, Arlington Heights, Illinois, United States
🇺🇸
Dana Farber, Boston, Massachusetts, United States
🇨🇦
University of Toronto - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

and more 204 locations

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Everolimus
Drug: Fluorouracil
Drug: Letrozole
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2016-04-18

Last Posted Date: 2021-09-23

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 40

Registration Number: NCT02742051

Locations: 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Phase 1

Completed

Conditions: Stage IIA Gastric Cancer AJCC v7
Gastroesophageal Junction Adenocarcinoma
Gastric Cardia Adenocarcinoma
Stage II Gastric Cancer AJCC v7
Stage IIIA Gastric Cancer AJCC v7
Stage IIIB Gastric Cancer AJCC v7
Stage IB Gastric Cancer AJCC v7
Stage IIB Gastric Cancer AJCC v7

Interventions: Drug: Carboplatin
Procedure: Computed Tomography
Drug: Fluorouracil
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Oxaliplatin
Drug: Paclitaxel
Biological: Pembrolizumab
Procedure: Positron Emission Tomography
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2016-04-06

Last Posted Date: 2024-04-18

Lead Sponsor: Mayo Clinic

Target Recruit Count: 31

Registration Number: NCT02730546

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab
Drug: 5-FU
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Nab-Paclitaxel
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2016-03-22

Last Posted Date: 2021-07-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 243

Registration Number: NCT02715531

Locations: 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 27 locations

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma of the Bladder

Interventions: Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin
Radiation: Intensity modulated radiation therapy (IMRT)
Procedure: Transurethral Resection of Bladder tumor
Drug: 5-FU
Drug: Mitomycin C

First Posted Date: 2016-03-17

Last Posted Date: 2024-12-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 78

Registration Number: NCT02710734

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Sidney kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 1 locations